Previous 10 | Next 10 |
CHICAGO , Jan. 27, 2020 /PRNewswire/ -- Private investor, Ronald Chez , increases Alimera position. Media contact: Elias Matsakis , Holland & Knight LLP View original content: http://www.prnewswire.com/news-releases/alimera-sciences-inc-13da-filing-300992952.html SOUR...
Three-year interest-only period Additional $2.5 million available under certain conditions ATLANTA, Jan. 06, 2020 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a leader in the commercialization and development of prescription ophthalmology tre...
CHICAGO , Dec. 11, 2019 /PRNewswire/ -- Ronald L Chez, a private investor, files a 13D for Alimera Sciences, Inc. (NASDAQ: ALIM). Alimera returns to growth in the 3 rd quarter and expects continued progress in the 4 th quarter. The Company is in a strong position to succeed with their u...
ATLANTA, Dec. 04, 2019 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera” or “Company”), a leader in the commercialization and development of prescription ophthalmology treatments for the management of retinal diseases, today announces that Rick...
Company continues to execute on its international expansion strategy ATLANTA, Dec. 03, 2019 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a leader in the commercialization and development of prescription ophthalmology treatments for the management...
Our weekend preview of upcoming IPOs, earnings reports, conference presentations, investor days, IPO lockup expirations, FDA decisions, Barron's mentions and other key events that could impact stocks, and our single stock focus. If you are interested in listening to Stocks To Watch t...
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha , Apple ...
ATLANTA, Nov. 26, 2019 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera” or “Company”), a leader in the commercialization and development of prescription ophthalmology treatments for the management of retinal diseases, today announces that Rick...
The NASDAQ Biotechnology Index (INDEXNASDAQ: NBI ) had a bit of a rocky week, but managed to stay in the green over the course of the trading period. The index opened last Monday (November 11) at 3,459.2 points before reaching 3,492.46 points as of 1:33 p.m. EST on Friday (November 15)...
ATLANTA, Nov. 14, 2019 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a leader in the commercialization and development of prescription ophthalmology treatments for the management of retinal diseases, announces that it has filed a certificate of amendme...
News, Short Squeeze, Breakout and More Instantly...
Alimera Sciences Inc. Company Name:
ALIM Stock Symbol:
NASDAQ Market:
Alimera Sciences Inc. Website:
2024-07-07 16:40:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
NEW YORK, NY / ACCESSWIRE / July 3, 2024 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Perficient, Inc. (NASDAQ:PRFT)'s sal...
NEW YORK, NY / ACCESSWIRE / June 26, 2024 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Alimera Sciences, Inc. (NASDAQ:ALIM)'...